RGN-259 is a preservative-free ophthalmic solution containing thymosin beta-4, investigated for dry eye disease and neurotrophic keratopathy. It is an interesting counterpoint to the injectable TB-500 products sold online, because it represents the same molecule pursued through a proper development pathway.
This guide situates RGN-259 within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
Why the eye makes sense
Thymosin beta-4 binds actin and influences cell migration, has anti-inflammatory activity, and promotes epithelial repair. Those properties map well onto the ocular surface, where the problem in both dry eye and neurotrophic keratopathy is a failure of the corneal epithelium to maintain or restore itself against inflammation and impaired healing.
The delivery advantage is substantial and worth naming explicitly. The ocular surface is directly accessible. A drop places the peptide precisely on the target tissue at a controlled concentration, repeatedly, without systemic exposure — the same reason topical PDGF reached approval for wound healing while systemic growth factor therapy did not.
For peptides in general, delivery is frequently the limiting factor rather than biology. Where the target is a surface, that limitation largely disappears.
What the trials found
RGN-259 has been evaluated in clinical trials for dry eye disease and for neurotrophic keratopathy, a serious condition in which corneal sensory innervation is impaired and the epithelium fails to heal.
The dry eye program produced mixed results across trials. Some studies met certain sign or symptom endpoints while others did not replicate the findings consistently. This is a common pattern in dry eye research and not unique to this agent: the condition has notoriously variable endpoints, a poor correlation between objective signs and patient-reported symptoms, and a substantial placebo response, all of which make demonstrating benefit difficult.
Work in neurotrophic keratopathy addressed a smaller population with a clearer and more objective endpoint — corneal healing.
The honest summary is a compound with a rational mechanism and a trial record that has not yet produced a definitive approval.
What this says about TB-500 products
RGN-259 is worth knowing mainly for the contrast it draws. The same molecule — thymosin beta-4 — is sold widely online as injectable TB-500 for tissue repair and recovery, on the basis of preclinical data and user reports.
RGN-259 shows what pursuing that molecule properly looks like: a defined formulation, a specified indication, a delivery route matched to the target, controlled trials with pre-specified endpoints, and results that are then reported whether or not they are favorable.
The comparison is not an argument that thymosin beta-4 does nothing. It is that the difference between an investigational drug and a research chemical is the presence of that apparatus — and that the mixed trial results are precisely the kind of information the unregulated market never generates.
Status
RGN-259 is investigational and not FDA-approved. Development status for compounds at this stage changes, and current status should be verified rather than assumed from older material.
Patients with dry eye or neurotrophic keratopathy should be managed with established approaches under ophthalmologic care. Our peptide formulary tracks status across the category.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering peptide delivery route and development pathways, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →